SAREPTA THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition
SAREPTA THERAPEUTICS, INC. (SRPT) reported APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition of $28.03 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition · last filed 2026-08-05
- SAREPTA THERAPEUTICS, INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2026-06-30 was $28.03M, a 32.65% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2026-03-31 was $33.67M, a 27.67% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2025-09-30 was $16.40M, a 66.54% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2025-06-30 was $41.62M, a 25.22% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2025 was $139.08M, a 32.20% decline from fiscal 2024.
- SAREPTA THERAPEUTICS, INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2024 was $205.13M, a 12.39% increase from fiscal 2023.
- SAREPTA THERAPEUTICS, INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2023 was $182.51M, a 21.67% decline from fiscal 2022.
- SAREPTA THERAPEUTICS, INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2022 was $233.02M, a 104.50% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 365 month |
|---|---|---|---|---|---|
| 2026-06-30 | $28.03M 10-Q · filed 2026-08-05 | $61.70M derived: sum of 2 quarters · filed 2026-08-05 | |||
| 2026-03-31 | $33.67M 10-Q · filed 2026-08-05 | ||||
| 2025-12-31 | $139.08M 10-K · filed 2026-03-02 | ||||
| 2025-09-30 | $16.40M 10-Q · filed 2025-11-06 | $58.01M derived: sum of 2 quarters · filed 2026-08-05 | $104.57M derived: sum of 3 quarters · filed 2026-08-05 | ||
| 2025-06-30 | $41.62M 10-Q · filed 2026-08-05 | $88.17M derived: sum of 2 quarters · filed 2026-08-05 | |||
| 2025-03-31 | $46.56M 10-Q · filed 2026-08-05 | ||||
| 2024-12-31 | $205.13M 10-K · filed 2026-03-02 | ||||
| 2024-09-30 | $49.00M 10-Q · filed 2025-11-06 | $104.65M derived: sum of 2 quarters · filed 2025-11-06 | $149.85M derived: sum of 3 quarters · filed 2025-11-06 | ||
| 2024-06-30 | $55.65M 10-Q · filed 2025-11-06 | $100.86M derived: sum of 2 quarters · filed 2025-11-06 | |||
| 2024-03-31 | $45.20M 10-Q · filed 2025-11-06 | ||||
| 2023-12-31 | $182.51M 10-K · filed 2026-03-02 | ||||
| 2023-09-30 | $48.06M 10-Q · filed 2024-11-06 | $95.44M derived: sum of 2 quarters · filed 2024-11-06 | $136.69M derived: sum of 3 quarters · filed 2024-11-06 | ||
| 2023-06-30 | $47.38M 10-Q · filed 2024-11-06 | $88.63M derived: sum of 2 quarters · filed 2024-11-06 | |||
| 2023-03-31 | $41.25M 10-Q · filed 2024-11-06 | ||||
| 2022-12-31 | $233.02M 10-K · filed 2025-02-28 | ||||
| 2022-09-30 | $50.42M 10-Q · filed 2023-11-01 | $153.31M derived: sum of 2 quarters · filed 2023-11-01 | $182.51M derived: sum of 3 quarters · filed 2023-11-01 | ||
| 2022-06-30 | $102.89M 10-Q · filed 2023-11-01 | $132.09M derived: sum of 2 quarters · filed 2023-11-01 | |||
| 2022-03-31 | $29.20M 10-Q · filed 2023-11-01 | ||||
| 2021-12-31 | $113.94M 10-K · filed 2024-02-28 | ||||
| 2021-09-30 | $26.68M 10-Q · filed 2022-11-02 | $55.65M derived: sum of 2 quarters · filed 2022-11-02 | $84.16M derived: sum of 3 quarters · filed 2022-11-02 | ||
| 2021-06-30 | $28.97M 10-Q · filed 2022-11-02 | $57.48M derived: sum of 2 quarters · filed 2022-11-02 | |||
| 2021-03-31 | $28.51M 10-Q · filed 2022-11-02 | ||||
| 2020-12-31 | $108.07M 10-K · filed 2023-02-28 | ||||
| 2020-09-30 | $26.90M 10-Q · filed 2021-11-03 | $54.52M derived: sum of 2 quarters · filed 2021-11-03 | $78.54M derived: sum of 3 quarters · filed 2021-11-03 | ||
| 2020-06-30 | $27.62M 10-Q · filed 2021-11-03 | $51.64M derived: sum of 2 quarters · filed 2021-11-03 | |||
| 2020-03-31 | $24.02M 10-Q · filed 2021-11-03 | ||||
| 2019-12-31 | $78.60M 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | $20.64M 10-Q · filed 2020-11-05 | $40.40M derived: sum of 2 quarters · filed 2020-11-05 | $56.54M derived: sum of 3 quarters · filed 2020-11-05 | ||
| 2019-06-30 | $19.76M 10-Q · filed 2020-11-05 | $35.90M derived: sum of 2 quarters · filed 2020-11-05 | |||
| 2019-03-31 | $16.14M 10-Q · filed 2020-11-05 | ||||
| 2018-12-31 | $50.13M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $11.48M 10-Q · filed 2019-11-07 | $26.76M derived: sum of 2 quarters · filed 2019-11-07 | $37.29M derived: sum of 3 quarters · filed 2019-11-07 | ||
| 2018-06-30 | $15.28M 10-Q · filed 2019-11-07 | $25.80M derived: sum of 2 quarters · filed 2019-11-07 | |||
| 2018-03-31 | $10.53M 10-Q · filed 2019-11-07 | ||||
| 2017-12-31 | $30.46M 10-K · filed 2020-02-26 | ||||
| 2016-12-31 | $30.11M 10-K · filed 2019-02-28 | ||||
| 2015-12-31 | $32.12M 10-K · filed 2018-03-01 | ||||
| 2014-12-31 | $20.34M 10-K · filed 2017-02-28 | ||||
| 2013-12-31 | $11.13M 10-K · filed 2016-02-25 | ||||
| 2012-12-31 | $3.08M 10-K · filed 2015-02-26 | ||||
| 2011-12-31 | $3.13M 10-K · filed 2014-03-03 | ||||
| 2010-12-31 | $21.42M 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |